Composition based on moringa oleifera, ashwagandha and shatavari

Abstract

The invention relates to a composition comprising at least 40% by weight of Moringa oleifera, at least 5% by weight of Ashwagandha, and between 0.5 and 20% by weight of Shatavari, the percentages by weight being based on the total weight of the composition. The invention also relates to a method for preparing the composition and to the uses of the composition as a medicine or food supplement, in particular for treating gastric ulcers.

Description

[0001] Description

[0002] Title: Composition based on Moringa olifeira, Ashwagandha and Shatavari

[0003] TECHNICAL FIELD OF THE INVENTION

[0004]

[0001] The invention relates to a composition comprising a mixture of plants selected from Moringa olifeira, Ashwagandha, Shatavari and, optionally, Alfalfa.

[0005] STATE OF THE TECHNOLOGY

[0006]

[0002] Gastric ulcers are a common condition. For example, in the world of racehorses, gastric ulcers often result from the intense stress to which these animals are subjected. Rigorous training involving physical exertion, the successive changes in their environment during travel for competitions, and the competitive and noisy environments are all factors that contribute to the development of these ulcers.

[0007]

[0003] Several methods exist for preventing and treating gastric ulcers. Pharmacological treatments consist mainly of administering anti-ulcer drugs such as proton pump inhibitors and H2 antagonists, which reduce the production of gastric acid. Omeprazole is one of the most widely used treatments for this type of condition.

[0008]

[0004] In addition to drug treatments, management and prevention methods are also used. These include improving living conditions and diet. Stress reduction through techniques such as modulating the training environment and dividing meals into smaller but more frequent portions are strategies often used to minimize the occurrence of gastric ulcers.

[0009]

[0005] However, it is well known that pharmacological treatments, such as proton pump inhibitors (PPIs) and H2 antagonists, can cause undesirable side effects, including long-term nutritional deficiencies. Furthermore, these pharmacological treatments are expensive, and many ulcer patients therefore go untreated. Finally, the management and prevention methods described above require ongoing management and may not always be effective.

[0010]

[0006] The present invention aims to overcome all or part of the drawbacks of the prior art mentioned above. In particular, the present invention is an effective alternative to current techniques for treating gastric ulcers, especially in horses. Indeed, the present invention reduces side effects, dependence, and costs (4 to 15 times less than pharmacological treatments), while offering a more manageable and natural health solution.

[0007] To this end, the invention relates to a composition comprising at least 40% by weight of Moringa olifeira, at least 5% by weight of Ashwagandha, and between 0.5 and 20% by weight of Shatavari, the weight percentages being given on the total weight of the composition.

[0011]

[0008] It should be noted that in the context of this application, and unless otherwise stipulated, the ranges of values ​​indicated are understood to include the limits.

[0012]

[0009] The composition according to the invention is an edible composition, enabling the prevention and / or reduction of gastric ulcers, particularly in mammals and especially in horses.

[0013]

[0010] Moringa olifeira, also called winged ben, is a plant species of the genus Moringa in the monotypic family Moringaceae, native to India, Sri Lanka and West Africa

[0014]

[0011] Advantageously, the whole plant or a part of the plant may be used. Advantageously, the part of the Moringa olifeira plant used in the composition according to the invention is chosen from the leaf, bark, flower, root, or mixtures thereof. Preferably, the part of the Moringa olifeira plant used in the composition according to the invention is the leaf or the root.

[0015]

[0012] Preferably, the composition according to the invention comprises between 40% and 70% by weight of Moringa olifeira, more preferably between 45% and 65% by weight, even more preferably between 45% and 60% by weight, for example between 52% and 58% by weight, the percentage by weight being given on the total weight of the composition.

[0016]

[0013] Ashwagandha, also known as Withania somnifera, is a plant in the Solanaceae family. It is native to India.

[0017]

[0014] Advantageously, the whole plant or a part of the plant may be used. Advantageously, the part of the Ashwagandha plant used in the composition according to the invention is chosen from the leaf, bark, flower, root, or a mixture thereof. Preferably, the part of the Ashwagandha plant used in the composition according to the invention is the leaf or the root.

[0018]

[0015] Preferably, the composition according to the invention comprises between 5% and 40% by weight of Ashwagandha, more preferably between 15% and 40% by weight of Ashwagandha, even more preferably between 20% and 40% by weight, for example between 25% and 35% by weight, the percentage by weight being given on the total weight of the composition.

[0019]

[0016] Shatavari, also called Asparagus racemosus, is a plant species native to Africa, southern Asia, including the Indian subcontinent, as far north as Australia.

[0020]

[0017] Advantageously, the whole plant or a part of the plant can be used. Advantageously, the part of the Shatavari plant used in the composition according to the invention is chosen from the leaf, bark, flower, root, or a mixture thereof. Preferably, the part of the Shatavari plant used in the composition according to the invention is the leaf or the root.

[0021]

[0018] Preferably, the composition according to the invention comprises between 1% and 20% by weight of Shatavari, more preferably between 1% and 15% by weight, even more preferably between 2% and 10% by weight, for example between 2% and 8% by weight, the percentage by weight being given on the total weight of the composition.

[0022]

[0019] The amount of Shatavari in the composition should not exceed 20% because the inventors have shown that an overdose would be detrimental to the stomach, as it would cause hyperacidity, which is particularly harmful to stomachs with ulcerous lesions, and thus lead to an effect contrary to healing.

[0023]

[0020] Optionally, the composition according to the invention may include Alfalfa.

[0024]

[0021] Alfalfa, also called cultivated lucerne, is a species of dicotyledonous plant of the family Fabaceae, subfamily Faboideae, native to the Near East and Central Asia.

[0025]

[0022] Advantageously, the whole plant or a part of the plant may be used. Advantageously, the part of the alfalfa plant used in the composition according to the invention is selected from the leaf, bark, flower, and / or root. Preferably, the part of the alfalfa plant used in the composition according to the invention is the leaf or the root.

[0026]

[0023] Preferably, the composition according to the invention comprises between 1% and 40% by weight of Alfalfa, more preferably between 1% and 30% by weight, even more preferably between 5% and 17% by weight, for example between 5% and 13% by weight, the percentage by weight being given on the total weight of the composition.

[0027]

[0024] According to an advantageous embodiment, the composition according to the invention comprises between 40% and 70% by weight of Moringa olifeira, between 5% and 40% by weight of Ashwagandha, between 1% and 20% by weight of Shatavari, and between 1% and 40% by weight of Alfalfa, the percentages by weight being given on the total weight of the composition.

[0028]

[0025] For example, the composition according to the invention may comprise between 45% and 65% by weight of Moringa olifeira, between 15% and 40% by weight of Ashwagandha, between 1% and 15% by weight of Shatavari, and between 1% and 30% by weight of Alfalfa, the percentages by weight being given on the total weight of the composition.

[0029]

[0026] Preferably, the composition according to the invention comprises between 45% and 60% by weight of Moringa olifeira, between 20% and 40% by weight of Ashwagandha, between 2% and 10% by weight of Shatavari, and between 5% and 17% by weight of Alfalfa, the percentages by weight being given on the total weight of the composition.

[0030]

[0027] According to a preferred embodiment, the composition according to the invention comprises between 52% and 58% by weight of Moringa olifeira, between 25% and 35% by weight of Ashwagandha, between 2% and 8% by weight of Shatavari, and between 5% and 13% by weight of Alfalfa, the percentages by weight being given on the total weight of the composition.

[0031]

[0028] The composition according to the invention advantageously has a moisture content of between 1 and 15%. Preferably, the moisture content of the composition according to the invention is between 1 and 10%, and even more preferably between 1 and 8%, such as, for example, between 2 and 8%. Such moisture levels allow for better preservation of the composition.

[0032]

[0029] The composition according to the invention may optionally include additional ingredients such as vitamins and / or minerals.

[0033]

[0030] By "additional ingredients" we mean ingredients which are added to the composition, in addition to those already naturally present (indeed, each plant can provide a given quantity of minerals and / or vitamins)

[0034]

[0031] According to a first embodiment, the composition consists of Moringa olifeira, Ashwagandha and Shatavari.

[0035]

[0032] According to a second preferred embodiment, the composition consists of Moringa olifeira, Ashwagandha, Shatavari and Alfalfa.

[0036]

[0033] Advantageously, the composition according to the invention is in the form of a powder or granules.

[0037]

[0034] Advantageously, when the composition is in powder form, the particle size is between 0.1 and 0.5 mm, more advantageously, between 0.15 and 0.25 mm, such as between 0.17 and 0.22 mm.

[0038]

[0035] Advantageously, when the composition is in the form of granules, the size of the latter is between 0.7 and 10.0 mm, more advantageously between 0.7 and 2.0 mm, such as between 0.8 and 1.4 mm.

[0039]

[0036] The sizes indicated above are measured using sieves (such as a sieve with a mesh opening of 70-80 mesh for powder or a sieve with a mesh opening of 15-20 mesh for granules).

[0040]

[0037] Furthermore, when the composition is in the form of granules, the granules may be individual or agglomerated. Agglomerated granules have various shapes, such as a wafer shape. Advantageously, a wafer is formed by agglomerating at least two granules, preferably three granules.

[0041]

[0038] The use of the composition in powder or granule form offers advantages in terms of storage and transport.

[0042]

[0039] Preferably, the composition is in the form of granules. Such a formulation avoids the production of potentially harmful dust during ingestion.

[0040] The invention also relates to a method for preparing a composition according to the invention, comprising the following steps:

[0043] - recovery of at least some of the following plants: Moringa olifeira, Ashwagandha, Shatavari and optionally Alfalfa,

[0044] - mixing of said plant parts.

[0041] By "recovery" of at least a part of the plants, we mean a step of supplying said plants or plant parts from supplier(s) / producer(s), for example following their harvest and drying.

[0045]

[0042] By "at least a part of the plant" is meant the whole plant or a part of the plant. Advantageously, the part of the plant used in the process according to the invention is chosen from the leaf, the bark, the flower, the root, or a mixture thereof. Preferably, the part of the plant used in the process according to the invention is the leaf or the root.

[0046]

[0043] Optionally, following this recovery step, the recovered plants or plant parts may undergo an initial cleaning step. This cleaning step allows, in particular, the removal of any impurities, dust, or foreign bodies that may be present. After the cleaning step, the recovered plants or plant parts are cleaned.

[0047]

[0044] Advantageously, the recovery and optionally cleaning step can be followed by a selection step.

[0048]

[0045] By "selection," we mean a step aimed at separating the recovered or cleaned plants or plant parts from other plants or plant parts of lesser quality (leaves that are too small, discolored, wilted, etc.). In particular, selection can be carried out by manual or mechanical sorting. This notably allows for optimizing the quality of the plants, thus ensuring the effectiveness and safety of the composition.

[0049]

[0046] According to a first embodiment of the process according to the invention, the plants or parts of plants recovered, cleaned or selected are then mixed.

[0050]

[0047] After the mixing step, said mixture may be subjected to a grinding step, a second cleaning.

[0051]

[0048] Advantageously, the grinding is carried out using a "tea-cut" (or "T-cut") type machine.

[0052]

[0049] The optional second cleaning step allows the dust to be removed, in particular that which may have been produced during grinding.

[0053]

[0050] According to a second embodiment of the process according to the invention, the plants or parts of plants recovered, cleaned or selected can be ground and / or cleaned a second time before the mixing step.

[0054]

[0051] At the end of the first or second embodiment of the process according to the invention, a composition according to the invention is obtained. In this case, the composition according to the invention is in tea-cut form.

[0055]

[0052] The composition according to the invention may, however, undergo a shaping step, in powder or granule form. Shaping into powder form is advantageously carried out by spraying, while shaping into granules is carried out by granulation and / or extrusion. Spraying, granulation, or extrusion is performed by any technique well known to those skilled in the art. Examples of granulation processes include dry granulation, wet granulation, pressing, fluidized bed spraying, and shearing.

[0056]

[0053] The granules can then be agglomerated to form wafers.

[0057]

[0054] The form of granules or wafers makes it possible to limit potential heterogeneity of the composition (in terms of particle size / density between the different plants), to avoid the production of dust, to ensure better preservation of the composition, to facilitate the transport of the composition and to facilitate feeding.

[0058]

[0055] According to a preferred embodiment, the process for preparing a composition according to the invention comprises: a step of recovering the leaves of the following plants: Moringa olifeira, Ashwagandha, Shatavari and optionally Alfalfa, a step of first cleaning and / or selection of the leaves;

[0059] - a step of mixing and then grinding the leaves; or alternatively, a step of grinding and then mixing the leaves.

[0060]

[0056] According to an alternative embodiment, the process for preparing a composition according to the invention comprises:

[0061] - a step involving the collection of leaves from the following plants: Moringa olifeira, and optionally Alfalfa,

[0062] - a step of recovering the roots of the following plants: Ashwagandha and Shatavari

[0063] - a first cleaning and / or selection stage of the leaves and roots;

[0064] - a step of mixing then grinding the leaves and roots; or alternatively, a step of grinding then mixing the leaves and roots.

[0065]

[0057] Optionally, the process according to the invention may include a conditioning and / or storage step.

[0066]

[0058] Advantageously, the packaging can be carried out using properly sealed containers, such as plastic bags or large bags (“big bags”). Storage can be carried out in a warehouse at ambient temperature, protected from moisture.

[0067]

[0059] This packaging and / or storage makes it possible to limit as much as possible any contamination or deterioration.

[0068]

[0060] The invention also relates to a composition according to the invention, for use as a medicinal product.

[0069]

[0061] Advantageously, the composition according to the invention is designed for use in the treatment of gastric ulcers.

[0062] Alternatively, the composition according to the invention can be formulated as a food supplement. The invention then relates to a food supplement comprising or consisting of the composition according to the invention.

[0070]

[0063] Thus, the invention relates to a food supplement comprising or consisting of the composition according to the invention for its use in the treatment of gastric ulcers.

[0071]

[0064] The treatment carried out by the composition according to the invention as a medicinal product or food supplement can be preventive or curative.

[0072]

[0065] Furthermore, the composition according to the invention, as a medicinal product or food supplement, is suitable for use in the treatment of gastric ulcers in humans or animals. The medicinal product or supplement can therefore be for human or veterinary use.

[0073]

[0066] Advantageously, the composition according to the invention as a medicinal product or food supplement is suitable for use in the treatment of gastric ulcers in animals and in particular cats, dogs, equines (horses, donkeys), ostriches, camelids (camels, dromedaries) or ruminants (cattle, sheep, goats).

[0074]

[0067] The composition according to the invention as a medicinal product or food supplement is particularly suitable for use in the treatment of gastric ulcers in humans or animals under stress.

[0075]

[0068] Therefore, the composition according to the invention, as a medicinal product or dietary supplement, is suitable for use in the treatment of gastric ulcers in horses, and in particular in racehorses and / or sport horses. Indeed, these horses are subjected to stress, which frequently results in the development of gastric ulcers. Furthermore, it has been demonstrated that the composition according to the invention does not fall into the category of doping products. More generally, the composition according to the invention is suitable for any racing animal, such as, for example, camels or dromedaries.

[0076]

[0069] Advantageously, the composition according to the invention, as a medicinal product or food supplement, is formulated so as to be administered orally.

[0070] According to a first embodiment, when the composition according to the invention is administered to horses, it is administered orally on a daily basis.

[0077]

[0071] Advantageously, when the composition according to the invention is used in the treatment of gastric ulcers in a horse, it is administered at a dose of between 30 and 60 g / day.

[0078]

[0072] Preferably, the composition according to the invention is administered at a dose of between 30 and 55 mg / day, for example 35 or 50 mg / day.

[0073] Advantageously, such a dose is administered in one or more doses, preferably in a single dose. For example, this administration can be carried out when feeding the animal.

[0079]

[0074] According to a second embodiment, when the composition according to the invention is used in the treatment of gastric ulcers in a human, it is administered at a dose of between 2 and 7 g / day.

[0080]

[0075] Preferably, the composition according to the invention is administered at a dose of between 3 and 6 g / day, for example 4 and 5 g / day.

[0081]

[0076] Advantageously, the administration of such a dose is done in one or more doses, preferably in a single dose.

[0082]

[0077] Particularly advantageously, the composition according to the invention for its use as a medicinal product or food supplement according to the invention is packaged in the form of tablets, powder, capsules, tea bags, soft capsules, granules, wafers.

[0083]

[0078] Particularly advantageously, the form of powder, granules or wafers is particularly suitable for administration to an animal, such as a horse.

[0084]

[0079] Other advantages, purposes and special features of the present invention will become apparent from the examples and figures that follow.

[0085]

[0080] Description of the figures:

[0086] - [Fig. 1] Figure 1 shows an image of the stomach wall, obtained by gastroscopy, in a mare diagnosed with a grade 3 ulcer before any treatment.

[0087] - [Fig. 2] Figure 2 shows the image of the stomach wall of the same mare (illustrated in figure 1) after 30 days of treatment.

[0088]

[0081] Example 1: Method for preparing two compositions according to the invention

[0089]

[0082] The compositions according to the invention are prepared from dried leaves of Moringa olifeira, Ashwagandha, Shatavari and Alfalfa. Said dried leaves are collected directly from producers.

[0090]

[0083] Upon receipt of the sheets, they are processed according to the steps below.

[0091]

[0084] Step 1: Initial cleaning

[0092]

[0085] The recovered leaves are first thoroughly cleaned with water to remove any impurities, dust, or foreign matter that may be present. This ensures that only clean raw materials are used. At the end of this step 1, the leaves are said to be cleaned.

[0086] Step 2: Selection of the cleaned leaves

[0093]

[0087] The cleaned leaves are carefully selected to recover the best leaves and separate them from the others of lesser quality (leaves that are too small, discolored or withered). The selection of the leaves is carried out manually.

[0094]

[0088] In addition, this step ensures the quality of the final product.

[0095]

[0089] Step 3: Mixing

[0096]

[0090] Following step 2, the plant leaves are then mixed in the following proportions:

[0097] 091] Percentages (%) by weight are expressed relative to the total weight of the mixture.

[0098]

[0092] Step 4: Grinding

[0099]

[0093] Each mixture is finally ground using a tea-cut type grinder. By "tea-cut" (or "T-cut") machine, we mean a machine commonly used for preparing tea leaves.

[0100]

[0094] Step 5: Second cleaning

[0101]

[0095] Each of the ground mixtures is cleaned a second time to remove any traces of dust.

[0102]

[0096] Alternatively, it is possible to perform step 3 after steps 4 and 5.

[0103]

[0097] Step 6: Granulation or spraying

[0104]

[0098] Once cleaned, each mixture can be granulated or pulverized.

[0105]

[0099] After granulation, the granule size is, for example, on the order of 15-20 mesh (0.85-1.19 mm).

[0100] After pulverization, the particle size is, for example, on the order of 70-80 mesh (0.18-0.21 mm).

[0106]

[0101] At the end of step 6, the compositions according to the invention or the comparative compositions, resulting from the different mixtures, are obtained. Thus, composition A is obtained from mixture A, composition B is obtained from mixture B, composition C is obtained from mixture C, comparative composition 1 is obtained from comparative mixture 1, comparative composition 2 is obtained from comparative mixture 2 and comparative composition 3 is obtained from comparative mixture 1.

[0107]

[0102] Example 2: Test on horses of composition A, for 30 days

[0108]

[0103] Composition A, obtained in Example 1, is tested on racehorses that have been diagnosed as having a gastric ulcer.

[0109]

[0104] The effects of composition A on the gastrointestinal health of horses were measured by gastroscopy, but also by detailed monitoring of the general health of the horses.

[0110]

[0105] A. General Status Monitoring:

[0111]

[0106] A monitoring sheet was used and completed on days 0 and 30 by the users. It includes parameters such as weight, behavior and appetite in 12 horses.

[0112]

[0107] The results are presented in Table 1 below:

[0113]

[0108] The data in Table 1 indicate a substantial improvement in general condition (weight, behavior, appetite and recovery capacity), suggesting the effectiveness of the administered treatment.

[0114]

[0109] To complement these observations, follow-up by gastroscopy was carried out.

[0115]

[0110] B. Monitoring by Gastroscopy

[0116]

[0111] The Protocol:

[0117]

[0112] Gastroscopy monitoring involves administering composition A for a specified period (30 days) and evaluation by gastroscopy, as follows:

[0118]

[0113] Initial Gastroscopy (JO): A baseline assessment of the gastrointestinal condition is performed prior to administration of composition A. This step establishes a reference on the initial state of the gastric mucosa.

[0119]

[0114] Gastroscopy at the End of Treatment (Day 30): A second gastroscopy is performed at the end of the one-month treatment period. This evaluation allows observation of structural changes in the mucosa due to the effect of the administered composition A.

[0120]

[0115] Composition A is administered daily at a dose of 35 grams, in a single dose during the distribution of the food ration.

[0121]

[0116] Results: The results of the study demonstrate a significant improvement in the condition of the stomach walls between day 0 (D0) and day 30 (D30). Indeed, on D0, the stomach walls showed significant damage, characterized by an irregular appearance accompanied by brown and red lesions, typical of a horse suffering from ulcers, classified as grade 3 on the EGUS scale. Figure 1 illustrates the presence of deep and wide ulcers, reaching the deep layers of the stomach wall, observed on D0. After a 30-day treatment period, observations (D30) reveal visibly improved stomach walls, with a bright, light pink tint, indicative of the normal color of the stomach of a healthy horse. Dissipation of inflammation was also observed. Figure 2 shows the stomach wall of the same horse, previously affected by ulcers (Figure 1).The mucous membrane is of uniform color, ranging from pale pink to white, without signs of excessive keratinization or inflammation, which indicates a healthy stomach.

[0122]

[0117] Example 3: Testing compositions C, 1, 2 and 3 on horses for 60 days

[0123]

[0118] Compositions C, 1, 2 and 3 of Example 1 were tested on 27, 30, 30 and 32 racehorses respectively, all diagnosed with a gastric ulcer. The tests were carried out over 60 days with a daily administration of 35 g.

[0124]

[0119] The effects of the aforementioned compositions were measured by a detailed monitoring of the general health status of the horses.

[0125]

[0120] A tracking sheet was used and completed by the users. The results are presented in Table 2 below:

[0126]

[0127]

[0121] The data in Table 2 highlight a synergy, particularly between Moringa and Ashwagandha. For example, regarding recovery after exercise, comparative composition 1 improves the condition of 70% of the horses, while comparative composition 2 results in an improvement for 60% of them. In comparison, composition 3—containing 70% Moringa and 30% Ashwagandha—provides an improvement in 88% of the horses. A similar observation is made, at least for stress reduction, recovery after exercise, and endurance. Furthermore, the data in Table 2 show that composition C, according to the invention, exhibits excellent efficacy, since it improves all the parameters tested (in particular stress) compared to the other compositions, and more specifically, the vitality, endurance, and recovery after exercise of all the horses.

Claims

Demands 1. Composition comprising at least 40% by weight of Moringa olifeira, at least 5% by weight of Ashwagandha, and between 0.5 and 20% by weight of Shatavari, the percentages by weight being given on the total weight of the composition.

2. Composition according to claim 1, comprising between 40% and 70% by weight of Moringa olifeira, the percentage by weight being given on the total weight of the composition.

3. Composition according to claim 1 or 2, comprising between 15% and 40% by weight of Ashwagandha, the percentage by weight being given on the total weight of the composition.

4. Composition according to any one of claims 1 to 3, comprising between 1% and 20% by weight of Shatavari, the percentage by weight being given on the total weight of the composition.

5. Composition according to any one of the preceding claims, comprising between 1% and 40% by weight of Alfalfa, the percentage by weight being given on the total weight of the composition.

6. Composition according to claim 1, comprising between 40% and 70% by weight of Moringa olifeira, between 5% and 40% by weight of Ashwagandha, between 1% and 20% by weight of Shatavari, and between 1% and 40% by weight of Alfalfa, the percentages by weight being given on the total weight of the composition.

7. Composition according to claim 6, comprising between 45% and 60% by weight of Moringa olifeira, between 20% and 40% by weight of Ashwagandha, between 2% and 10% by weight of Shatavari, and between 5% and 17% by weight of Alfalfa, the percentages by weight being given on the total weight of the composition.

8. A method for preparing a composition according to any one of claims 1 to 7, comprising the following steps: - recovery of at least some of the following plants: Moringa olifeira, Ashwagandha, Shatavari and optionally Alfalfa, - a mixture of said plant parts.

9. Composition according to any one of claims 1 to 7, for use as a medicinal product.

10. Composition according to claim 9, for use in the treatment of gastric ulcers.

11. Food supplement comprising or consisting of the composition according to any one of claims 1 to 7.

Images